Anavex Life Sciences Corp (AVXL)

[gbrown6332]

"FDA" and "logic" are rarely used in the same sentence, but it's worth noting again the FDA has approved and appears poised to approved new AD mAb treatments based on truncated trials, the thinnest of efficacy results and disturbing side effects, including patient deaths.

Logic suggests 2-73 shouldn't, nor will it, be held to a different and certainly not higher standard for AD approval than the suboptimal stuff the FDA has already approved. Full 2b/3 results inside an artfully crafted Kun Jin statistical data wrapper, will prove to be sufficient to convince the FDA to grant patient access. If a P4 is part of the AA bargain, so be it, no one will balk at that.